Dreyling, A. 2009. “Bendamustine Is a Hybrid Antimetabolite and Alkylating Agent Offering New Therapeutic Options for the Treatment of Non-Hodgkin Lymphomas”. Hematology Meeting Reports (formerly Haematologica Reports) 2 (5). https://doi.org/10.4081/hmr.v2i5.749.